RightFit Trial Directory

Lung Cancer clinical trials in Fargo, ND

14 recruiting lung cancer studies with a site in Fargo, ND.

All trials in Fargo, ND · All Lung Cancer trials

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Bismarck, ND · Fargo, ND · +1147 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Bismarck, ND · Fargo, ND · +278 more sites

RecruitingPhase 3NCT07513376

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Sponsor: Merck Sharp & Dohme LLC

Fargo, ND · Grand Forks, ND · +22 more sites

RecruitingPhase 2NCT06731907

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Sponsor: Merck Sharp & Dohme LLC

Fargo, ND · +4 more sites

RecruitingPhase 3NCT07388524

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Sponsor: National Cancer Institute (NCI)

Fargo, ND · +99 more sites

RecruitingPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Sponsor: Bristol-Myers Squibb

Bismarck, ND · Fargo, ND · +18 more sites

RecruitingPhase 2NCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Bismarck, ND · Fargo, ND · +275 more sites

RecruitingPhase 2NCT07293247

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Sponsor: Alliance for Clinical Trials in Oncology

Bismarck, ND · Fargo, ND · +108 more sites

RecruitingPhase 2NCT07252739

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Sponsor: Merck Sharp & Dohme LLC

Fargo, ND · +2 more sites

RecruitingPhase 1 / Phase 2NCT04165070

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Sponsor: Merck Sharp & Dohme LLC

Fargo, ND · +17 more sites

RecruitingPhase not listedNCT02012699

Integrated Cancer Repository for Cancer Research

Sponsor: University of Nebraska

Fargo, ND · Minot, ND · +40 more sites

RecruitingPhase 2NCT05642572

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Bismarck, ND · Fargo, ND · +451 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Bismarck, ND · Fargo, ND · +1226 more sites

RecruitingPhase 2NCT06769126

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Sponsor: SWOG Cancer Research Network

Bismarck, ND · Fargo, ND · +145 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.